Systemic lupus erythematosus (SLE)
Simone Appenzeller, MD, PhD
Unicamp
Campinas, São Paulo, Brazil
Disclosure(s): No financial relationships with ineligible companies to disclose
Hermine Brunner, MD, MSc, MBA
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Disclosure(s): AbbVie: Consultant (Ongoing); AstraZeneca-Medimmune: Consultant (Ongoing); Biogen: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb (BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); F-Hoffman La Roche: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKlein (GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Horizon: Consultant (Ongoing), Consultant (Ongoing); Janssen: Grant/Research Support (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Mark Mitsnefes, MD (he/him/his)
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Nephritis is a common organ involvement observed in childhood onset systemic lupus erythematosus and is associated with significant morbidity and mortality. Timely diagnosis and adequate treatment are essential to improve renal and overall outcome. Renal biopsy is still the gold standard for diagnosis, however several biomarkers have been validated for diagnosis and monitoring. Treatment in lupus nephritis should not only focus on renal remission, but also aim at controlling hypertension, preventing organ damage, and minimizing comorbidities and drug toxicity. In this session, we will focus on histology and biomarkers as prognostic markers and discuss the importance of anti-hypertensive and other non-immunological treatments.
Speaker: Simone Appenzeller, MD, PhD – Unicamp
Speaker: Hermine Brunner, MD, MSc, MBA – Cincinnati Children's Hospital Medical Center
Speaker: Mark Mitsnefes, MD (he/him/his) – Cincinnati Children's Hospital Medical Center
